Sign in
  Edit search
Cancer patients treated with sunitinib or sorafenib have suf…
Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination
Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination
Article, Chapter
Authors: S.F. Mulder
Publication: Clinical Cancer Research, Volume:17, Issue:13, Page(s):4541-4549
Published: American Association for Cancer Research, 2011
ISSN: 1078-0432
  Full text availability for this item
View Full Text Source:Clinical Cancer Research,Clinical Cancer Research,American Association for Cancer Research Opens in new Window
Journal:  Clinical Cancer Research Source:American Association for Cancer Research Opens in new Window
Collection:  American Association for Cancer Research Opens in new Window
Coverage:
  • 1995~present; volume:1~present
Browse related articles
  Print copies at your library
Check availability in RUQuest
  Request a copy of this item
Cite this item